Comparative Pharmacology
Head-to-head clinical analysis: PYOCIDIN versus TRIMPEX 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYOCIDIN versus TRIMPEX 200.
PYOCIDIN vs TRIMPEX 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
200 mg orally once daily, or 100 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with an additional 10-20% as hepatic metabolites excreted in bile and feces.
Category C
Category C
Antibiotic
Antibiotic